Sanofi Rezurock Wins EU Approval for Chronic GvHD
PARIS, France, March 31, 2026 Sanofi has received European Commission approval for Rezurock® (belumosudil) for the treatment of chronic...
Sanofi
Advertisement
Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
CHMP Backs Acoziborole for Sleeping Sickness
KINSHASA / PARIS / GENEVA / AMSTERDAM – February 27, 2026 The European Medicines Agency’s Committee for Medicinal Products...
Advertisements
Sensorion Secures €60M to Advance Gene Therapies for Hearing Loss
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Sanofi to Acquire Dynavax, Expanding Adult Vaccine Pipeline
Paris, France | December 24, 2025 — Sanofi announced that it has entered into a definitive agreement to acquire...
EU Approves Dupixent as First Targeted CSU Therapy
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
Advertisement
